4월 24일 14:34

Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. · Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1...

건강제약실적

3월 19일 15:19

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024. The diversity of Galderma’s p...

건강임상시험제약연구개발

3월 11일 09:15

Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis

Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 tri...

건강임상시험제약연구개발

2월 29일 15:36

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

Galderma: Delivered against full year guidance for another consecutive year with strong financial performance · Galderma achieved net sales of 4.082 B USD, up 8.5% year-on-year on a constant currency basis[1] in FY 2023, at the higher end of its 6...

건강제약실적

2월 28일 17:02

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading d...

건강임상시험제약연구개발